文献速递重症综合管理与镇静镇痛心脑血管急症

脑特异性血清生物标志物预测诊断多样化的儿科重症监护病房患者的神经学疾病负担

Brain-Specific Serum Biomarkers Predict Neurological Morbidity in Diagnostically Diverse Pediatric Intensive Care Unit Patients.
PubMed 文献 · Neurocrit Care · 2018-01-01
一句话结论在诊断多样化的PICU患儿中,第1-7天血清NSE、MBP和S100B峰值水平可独立预测出院时不良神经学结局(PCPC 3-6分且较基线恶化)。

该前瞻性研究纳入103例诊断多样化的PICU患儿,于入院第1-7天连续采集血清,用酶联免疫吸附试验测定NSE、MBP和S100B浓度。出院时不良神经学结局定义为PCPC评分3-6分且较基线恶化。不良结局组三种标志物峰值水平均显著高于良好结局组:NSE 39.4±44.1 vs 12.2±22.9 ng/ml(P=0.005),MBP 9.1±11.5 vs 0.6±1.3 ng/ml(P=0.003),S100B 130±232 vs 34±70 pg/ml(P=0.04)。控制原发神经科入院诊断和基线PCPC差后,各峰值水平仍独立相关(NSE P=0.04;MBP P=0.004;S100B P=0.04),ROC曲线下面积分别为NSE 0.75(0.58, 0.92)、MBP 0.81(0.66, 0.94)、S100B 0.80(0.67, 0.93)。作者认为血清生物标志物联合临床数据可用于构建模型,早期识别神经损伤。

要点

  • PICU患儿第1-7天血清NSE、MBP、S100B峰值水平越高,出院时不良神经学结局(PCPC 3-6分且较基线恶化)风险越高。
  • 不良结局组峰值:NSE 39.4±44.1 vs 12.2±22.9 ng/ml(P=0.005),MBP 9.1±11.5 vs 0.6±1.3 ng/ml(P=0.003),S100B 130±232 vs 34±70 pg/ml(P=0.04)。
  • 控制原发神经科入院诊断和基线PCPC差后,NSE(P=0.04)、MBP(P=0.004)、S100B(P=0.04)峰值均独立与不良神经学结局相关。
  • 预测不良神经学结局的ROC曲线下面积:NSE 0.75(0.58, 0.92)、MBP 0.81(0.66, 0.94)、S100B 0.80(0.67, 0.93)。
  • 作者认为血清生物标志物联合临床数据可构建模型,用于早期检测神经损伤,从而更及时地进行诊断和治疗干预。

适用人群与场景

  • 诊断多样化的儿科重症监护病房(PICU)患者,共103例,前瞻性连续纳入(原文未报告具体纳入和排除标准)。

诊断标准与关键阈值

  • 不良神经学结局定义:出院时儿科脑功能分类(PCPC)评分3-6分,且较基线恶化。

研究设计与关键结果

  • 研究类型:前瞻性研究,单中心(原文未明确写中心数,仅写PICU患者n=103),纳入诊断多样化的PICU患儿103例,于入院第1-7天采集血清,用酶联免疫吸附试验测定NSE、MBP和S100B。
  • 不良结局组 vs 良好结局组峰值水平(均值±标准差):NSE 39.4±44.1 vs 12.2±22.9 ng/ml(P=0.005);MBP 9.1±11.5 vs 0.6±1.3 ng/ml(P=0.003);S100B 130±232 vs 34±70 pg/ml(P=0.04)。
  • 控制原发神经科入院诊断和基线PCPC差后,逻辑回归分析显示各峰值水平独立与不良神经学结局相关:NSE P=0.04,MBP P=0.004,S100B P=0.04。
  • 预测不良神经学结局的ROC曲线下面积(95%CI):NSE 0.75(0.58, 0.92),MBP 0.81(0.66, 0.94),S100B 0.80(0.67, 0.93)。

证据类型、等级与局限

  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,血清脑特异性生物标志物(NSE、MBP、S100B)联合临床数据可用于构建模型,以早期检测PICU患儿的神经损伤,从而更及时地进行诊断和治疗干预,可能降低神经学疾病负担。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Unexpected neurological morbidity in Pediatric Intensive Care Units (PICUs) remains high and is difficult to detect proactively. Brain-specific biomarkers represent a novel approach for early detection of neurological injury. We sought to determine whether serum concentrations of neuron-specific enolase (NSE), myelin basic protein (MBP), and S100B, specific for neurons, oligodendrocytes, and glia, respectively, were predictive of neurological morbidity in critically ill children.

METHODS: Serum was prospectively collected on days 1-7 from diagnostically diverse PICU patients (n = 103). Unfavorable neurological outcome at hospital discharge was defined as Pediatric Cerebral Performance Category (PCPC) score of 3-6 with a deterioration from baseline. NSE, MBP, and S100B concentrations were measured by enzyme-linked immunosorbent assay.

RESULTS: Peak biomarker levels were greater in patients with unfavorable versus favorable neurological outcome [NSE 39.4 ± 44.1 vs. 12.2 ± 22.9 ng/ml (P = 0.005), MBP 9.1 ± 11.5 vs. 0.6 ± 1.3 ng/ml (P = 0.003), S100B 130 ± 232 vs. 34 ± 70 pg/ml (P = 0.04), respectively; mean ± SD]. Peak levels were each independently associated with unfavorable neurological outcome when controlling for presence of primary neurologic admission diagnosis and poor baseline PCPC using logistic regression analysis (NSE, P = 0.04; MBP, P = 0.004; S100B, P = 0.04), and had the following receiver operating characteristics: NSE 0.75 (0.58, 0.92), MBP 0.81 (0.66, 0.94), and S100B 0.80 (0.67, 0.93) (area under the curve [95% confidence intervals]).

CONCLUSIONS: Prospectively collected brain-specific serum biomarkers predict unfavorable neurological outcome in critically ill children. Serum biomarkers used in conjunction with clinical data could be used to generate models predicting early detection of neurological injury, allowing for more timely diagnostic and therapeutic interventions, potentially reducing neurological morbidity in the PICU.

来源:Neurocrit Care,查看原文。版权归原作者所有。

参考来源

  1. Au AK, Bell MJ, Fink EL, et al. Brain-Specific Serum Biomarkers Predict Neurological Morbidity in Diagnostically Diverse Pediatric Intensive Care Unit Patients. Neurocrit Care. 2018. PMID: 28612133. doi:10.1007/s12028-017-0414-7

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。